

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Rule 13d-101)

Under the Securities Exchange Act of 1934
(Amendment No. 4)

Immunogen, Inc.

(Name of Issuer)

Common Stock, \$.01 par value per share

(Title of Class of Securities)

45253H101

(CUSIP Number)

Stephen T. Burdumy, Esq.
Klehr, Harrison, Harvey, Branzburg & Ellers LLP
1401 Walnut Street
Philadelphia, PA 19102

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

January 7, 1998

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 5 Pages)

1 NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Capital Ventures International

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) / /

(b) / /

3 SEC USE ONLY

4 SOURCE OF FUNDS*

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

/ /

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

7 SOLE VOTING POWER

2,347,118

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

8 SHARED VOTING POWER

N/A

9 SOLE DISPOSITIVE POWER

2,347,118

10 SHARED DISPOSITIVE POWER

N/A

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,347,118

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES*

/ /

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.6%

14 TYPE OF REPORTING PERSON*

CO

*SEE INSTRUCTIONS BEFORE FILLING OUT

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Statement of
Reporting Persons (as defined below)Pursuant to Section 13(d) of the
Securities Exchange Act of 1934

in respect of

IMMUNOGEN, INC.

This Report filed by Capital Ventures International ("CVI") is the fourth amendment of its initial filing on Schedule 13D with respect to the common stock, \$.01 par value per share (the "Common Stock"), of Immunogen, Inc. (the "Company").

This Report relates to sales by CVI of an aggregate of 1,577,890 shares of Common Stock. Such sales took place in open market transactions between June 18, 1997 and January 7, 1998 at per share prices (net of brokerage commissions) of between \$0.85 and \$1.70.

Because the shares of Common Stock beneficially owned by CVI were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Company and were not acquired and are not held in connection with or as a participant in any transactions having such purpose or effect, any future changes in beneficial ownership will be reported on Schedule 13G rather than on this Schedule 13D.

Item 5. Interest in Securities of the Issuer.

Item 5 is hereby amended by the addition of the following at the end thereof:

"Between June 18, 1997 and October 15, 1997, CVI sold in open market transactions an aggregate of 729,329 shares of Common Stock at per share prices (net of brokerage commissions) of between \$1.23 and \$1.68. Such sales of Common Stock resulted in the receipt by CVI of aggregate net proceeds of approximately \$1,083,375. However, pursuant to the terms of the Company's Restated Articles of Organization and Warrants discussed above, CVI's beneficial ownership percentage remained at 9.9%.

During the period from July 31, 1997 through January 5, 1998, CVI converted its remaining 1,100 Preferred Shares (plus accrued dividends thereon) into 1,347,491 shares of Common Stock at Conversion Prices between \$0.85 and \$1.21 per share.

The following table sets forth certain information with respect to open market sales made by CVI of shares of Common Stock during the period from December 1, 1997 through January 7, 1998, representing all sales of Common Stock made by CVI during the 60 day period ending on January 7, 1998:

Date	Number of Shares	Price per Share	Aggregate Sale Price
-----	-----	-----	-----
12/1/97	55,000	\$1.1311	\$ 62,208
12/3/97	8,000	1.1049	8,839
12/4/97	7,500	1.1049	8,287
12/5/97	103,800	1.1888	123,397
12/8/97	67,100	1.2087	81,107
12/9/97	10,000	1.1049	11,049
12/12/97	8,000	1.1049	8,839
12/15/97	25,000	1.0737	26,843
12/16/97	11,000	1.0737	11,811
12/29/97	10,000	0.9175	9,175
12/31/97	10,000	0.8549	8,549
1/2/98	50,000	0.9175	45,873
1/5/98	288,500	1.0575	305,078
1/6/98	30,000	1.2966	38,898
1/6/98	100,000	1.3238	132,375
1/7/98	64,661	\$1.7022	\$110,069
	-----		-----
Total	848,561		\$992,397

As of January 7, 1998, CVI held (i) no shares of Common Stock and (ii) 2,347,118 Warrants. Based on the 24,884,325 shares of Common Stock outstanding on February 10, 1998, as reported in the Company's Form 10-Q, dated February 17, 1998, CVI held 8.6% of the outstanding shares of Common Stock.

To the best knowledge of CVI, none of the individuals listed in Item 2 hereof beneficially owns any shares of Common Stock other than through their ownership interest in CVI. Neither CVI, nor to the best of CVI's knowledge, any of the individuals listed in Item 2 hereof has effected any transactions in the Common Stock during the 60 day period ending on January 7, 1998, other than CVI's sale of an aggregate of 848,561 shares of Common Stock as described herein."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

CAPITAL VENTURES INTERNATIONAL

By: Susquehanna Advisors Group, Inc.
(f/k/a Bala International, Inc. and
Arbit, Inc.), pursuant to a Limited
Power of Attorney, a copy of which was
filed with the initial filing of this
Statement on Schedule 13D

By: /s/ Arthur Dantchik

Arthur Dantchik, President

Date: April 8, 1998
